Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $19.3 Million - $35.3 Million
-151,779 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $3.51 Million - $5.32 Million
-32,221 Reduced 17.51%
151,779 $20 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $10.3 Million - $15.9 Million
-97,000 Reduced 34.52%
184,000 $29.5 Million
Q2 2019

Aug 14, 2019

SELL
$115.0 - $141.58 $13 Million - $16 Million
-112,750 Reduced 28.63%
281,000 $39.8 Million
Q1 2019

May 15, 2019

SELL
$98.85 - $134.59 $7.74 Million - $10.5 Million
-78,250 Reduced 16.58%
393,750 $49.2 Million
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $11.8 Million - $20.3 Million
-184,500 Reduced 28.1%
472,000 $45.3 Million
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $15.8 Million - $20.2 Million
209,471 Added 46.86%
656,500 $49.8 Million
Q2 2018

Aug 14, 2018

BUY
$74.84 - $100.16 $9.51 Million - $12.7 Million
127,109 Added 39.73%
447,029 $37 Million
Q1 2018

May 15, 2018

SELL
$56.95 - $85.19 $2.62 Million - $3.92 Million
-46,041 Reduced 12.58%
319,920 $25.7 Million
Q4 2017

Feb 14, 2018

SELL
$22.57 - $63.56 $3.23 Million - $9.09 Million
-143,061 Reduced 28.11%
365,961 $23.1 Million
Q3 2017

Nov 13, 2017

BUY
$19.81 - $22.61 $10.1 Million - $11.5 Million
509,022
509,022 $11.5 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.